Clinical Trial Update: Study Using CABENUVA™ for the Treatment of Human Immunodeficiency Virus (HIV)-1, Administered in Infusion Centers (IC) or Alternate Sites of Administration (ASA) in the United States (U.S.) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating CABENUVA administered in infusion centers or alternate administration sites in the United States has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• CABENUVA (cabotegravir and rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 4 | Status: COMPLETED | Results posted: 2025-04-01